Testis
- Home
- Cancer Infomation
Testicular Germ Cell Tumors (TGCT)
Testicular cancer primarily affects younger men, most commonly diagnosed between the ages of 15 and 35. Even when the disease has spread to regional lymph nodes or distant organs, it remains highly responsive to treatment—with overall 5-year survival rates staying around 95% across all stages combined.
Etiology & Risk Factors
The pathogenesis of TGCT primarily involves the malignant transformation of Germ Cell Neoplasia In Situ (GCNIS), often rooted in fetal development.
Primary Causes & Environmental Triggers:
- Cryptorchidism (Undescended Testis): The most significant risk factor (4–8 fold increase). Even after orchiopexy, the risk remains elevated compared to the general population.
- Personal/Family History: A history of TGCT in the contralateral testis or a first-degree relative (brother > father) significantly increases risk.
- Infertility: There is a known biological link between subfertility and the development of TGCT (Testicular Dysgenesis Syndrome).
Genetic Predispositions:
- Isochromosome 12p [i(12p)]: A pathognomonic cytogenetic feature found in nearly all TGCTs.
- Specific Gene Mutations: Alterations in KIT, BAK1, and SPRY4 are associated with increased susceptibility.
- Klinefelter Syndrome (47,XXY): Associated specifically with mediastinal extragonadal germ cell tumors.
Clinical Manifestations (Symptoms)
Symptoms are often subtle, leading to a median diagnostic delay of 3–6 months.
Early-Stage Symptoms:
- Painless Mass: A firm, non-tender lump within the testis (hallmark presentation).
- Scrotal Heaviness: A dull ache or sensation of pulling in the lower abdomen or scrotum.
- Acute Pain: Occurs in ~10% of cases due to intratumoral hemorrhage or infarction.
Advanced-Stage Symptoms:
- Back/Flank Pain: Indicative of bulky retroperitoneal lymphadenopathy (N2–N3 disease).
- Pulmonary Symptoms: Cough or dyspnea from lung metastases.
- Supraclavicular Mass: Left-sided (Virchow’s node) involvement.
Paraneoplastic / Endocrine Syndromes:
- Gynecomastia: Breast tenderness or enlargement due to high levels of human chorionic gonadotropin (hCG) or estrogen/androgen imbalance.
Diagnostic Workup
The diagnostic pathway emphasizes avoiding “scrotal violation” to prevent aberrant lymphatic spread.
- 1. Scrotal Ultrasound: The initial imaging of choice; highly sensitive in differentiating intra-testicular from extra-testicular masses.
- 2. Serum Tumor Markers (Classic):
- Alpha-fetoprotein (AFP): Elevated in Non-Seminomas (never in pure Seminoma).
- beta-hCG: Elevated in both Seminomas and Non-Seminomas.
- LDH: A marker of tumor burden/turnover.
-
3. Radical Inguinal Orchidectomy: Both a diagnostic and therapeutic gold standard. The testis is delivered via an inguinal incision with high ligation of the spermatic cord at the internal ring.
Transscrotal biopsies are strictly contraindicated.
Common Investigations & Staging
Imaging Modalities & Rationale
- CT Abdomen and Pelvis: The primary modality for nodal staging, assessing the retroperitoneal lymph nodes (the first site of lymphatic spread).
- CT Chest: Mandatory in Non-Seminoma; optional in Seminoma unless abdominal CT is positive.
- Brain MRI: Reserved for high-risk metastatic disease (e.g., very high hCG or multiple lung nodules).
- 18F-FDG PET-CT: Not used for initial staging. Its primary role is evaluating residual masses in Seminoma after chemotherapy to distinguish fibrosis from viable tumor.
Treatment Overview
1. Surgery
- Radical High Inguinal Orchidectomy: Standard for all suspected malignancies.
- Testis-Sparing Surgery (TSS): Considered in 2026 for synchronous bilateral tumors, tumors in a solitary testis, or small indeterminate masses (<1cm) with negative markers.
- Robotic-Assisted Retroperitoneal Lymph Node Dissection (R-RPLND): Now standard for Stage II disease or as a primary option for high-risk Stage I Non-Seminoma. It offers nerve-sparing techniques to preserve ejaculatory function.
3. Systemic Therapy
- BEP Regimen: Bleomycin, Etoposide, and Cisplatin remains the standard. 3 cycles for "Good Risk" and 4 cycles for "Intermediate/Poor Risk."
- EP Regimen: 4 cycles of Etoposide/Cisplatin is used when Bleomycin is contraindicated (e.g., underlying lung disease or age >40).
- High-Dose Chemotherapy (HDCT) with Stem Cell Rescue: Reserved for relapsed or refractory disease.
2. Radiotherapy
- Adjuvant Para-aortic Radiation: Primarily used for Stage I or IIa Seminoma.
- Techniques: IMRT is preferred to minimize "low-dose bath" to the kidneys and bowel, reducing long-term secondary malignancy risks.
Emerging Therapies
- CAR-T Cell Therapy (e.g., BNT211): Targeting the oncofetal antigen Claudin-6 (CLDN6), showing significant promise in refractory germ cell tumors that have failed platinum-based therapy.
- AI-Driven Radiomics: AI algorithms now analyze CT surveillance scans to detect sub-centimetric nodal changes, reducing the "false positive" rate of salvage surgeries.
- miR-371-Guided Surveillance: A 2026 practice shift where serial miR-371 blood tests reduce the frequency of mandatory CT scans, lowering lifetime radiation exposure.
Medical Disclaimer
This information is for professional clinical and educational purposes only.
Testicular cancer management requires a multidisciplinary approach (Urology, Medical Oncology, Radiation Oncology).
Treatment decisions must be based on individual patient pathology, IGCCCG risk stratification, and the latest institutional protocols.